Work

Three-arm randomized phase II study of carboplatin (C) and paclitaxel (P) in combination with cetuximab (CET), IMC-A12, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508).

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.7516

Authors: Nasser H. Hanna, Suzanne Eleanor Dahlberg, Jill Kolesar, Fred R. Hirsch, Suresh S. Ramalingam, Joan H. Schiller

Institutions: Indiana University Indianapolis, Dana-Farber Cancer Institute, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, University of Colorado Cancer Center, Emory University, Winship Cancer Institute, The University of Texas Southwestern Medical Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2596954440

Cites:

Cited by: 3

Related to: 10